145 related articles for article (PubMed ID: 21737624)
21. Inhibitory action of alpha-difluoromethylornithine on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat urinary bladder carcinogenesis.
Uchida K; Seidenfeld J; Rademaker A; Oyasu R
Cancer Res; 1989 Oct; 49(19):5249-53. PubMed ID: 2504487
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
Yu DS; Lee CF; Hsieh DS; Chang SY
Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
[TBL] [Abstract][Full Text] [Related]
23. Aging and urinary bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Fukushima S; Shibata M; Tamano S; Ito N; Suzuki E; Okada M
J Natl Cancer Inst; 1987 Aug; 79(2):263-7. PubMed ID: 3474459
[TBL] [Abstract][Full Text] [Related]
24. Dose-dependent promoting effect of trisodium nitrilotriacetate monohydrate on urinary bladder carcinogenesis in Wistar rats pretreated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Kitahori Y; Konishi N; Shimoyama T; Hiasa Y
Jpn J Cancer Res; 1985 Sep; 76(9):818-22. PubMed ID: 3932279
[TBL] [Abstract][Full Text] [Related]
25. Possible mechanistic roles of anatomical and functional vascular changes in rat urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Tatematsu M; Lurie AG; Rippey RM; Conran PB; Arai M; Fukushima S; Ito N
Cancer Res; 1984 Jan; 44(1):278-84. PubMed ID: 6690039
[TBL] [Abstract][Full Text] [Related]
26. Significance of L-ascorbic acid and urinary electrolytes in promotion of rat bladder carcinogenesis.
Fukushima S; Shirai T; Hirose M; Ito N
Princess Takamatsu Symp; 1985; 16():159-68. PubMed ID: 3025161
[TBL] [Abstract][Full Text] [Related]
27. Trisodium nitriloacetate monohydrate: promoting effect in urinary bladder carcinogenesis in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Hiasa Y; Kitahori Y; Konishi N; Shimoyama T; Miyashiro A
J Natl Cancer Inst; 1985 Jan; 74(1):235-9. PubMed ID: 3855482
[TBL] [Abstract][Full Text] [Related]
28. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
[TBL] [Abstract][Full Text] [Related]
29. [Histological study of urinary bladder tumor: DNA of rat urinary bladder tumor caused by N-butyl-N-(4-hydroxybutyl) nitrosamine and that of human bladder tumor].
Murase T; Kobayashi O; Aota Y; Mitsuta H; Koshikawa T
Hinyokika Kiyo; 1983 Mar; 29(3):303-10. PubMed ID: 6677123
[TBL] [Abstract][Full Text] [Related]
30. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.
Yoshino T; Miyazaki J; Kojima T; Kandori S; Shiga M; Kawahara T; Kimura T; Naka T; Kiyohara H; Watanabe M; Yamasaki S; Akaza H; Yano I; Nishiyama H
PLoS One; 2019; 14(1):e0209196. PubMed ID: 30608942
[TBL] [Abstract][Full Text] [Related]
31. Mechanism responsible for the antitumor effect of BCG-CWS using the LEEL method in a mouse bladder cancer model.
Nakamura T; Fukiage M; Suzuki Y; Yano I; Miyazaki J; Nishiyama H; Akaza H; Harashima H
J Control Release; 2014 Dec; 196():161-7. PubMed ID: 25315488
[TBL] [Abstract][Full Text] [Related]
32. Local expression of cytokines in rat bladder carcinoma tissue after intravesical treatment with Nocardia rubra cell wall skeleton and bacille-Calmette-Guerin.
Rohde D; Gastl G; Biesterfeld S; Plante M; Jakse G
Urol Res; 1997; 25(1):19-24. PubMed ID: 9079741
[TBL] [Abstract][Full Text] [Related]
33. Optimization of cell-wall skeleton derived from Mycobacterium bovis BCG Tokyo 172 (SMP-105) emulsion in delayed-type hypersensitivity and antitumor models.
Miyauchi M; Murata M; Fukushima A; Sato T; Nakagawa M; Fujii T; Koseki N; Chiba N; Kashiwazaki Y
Drug Discov Ther; 2012 Aug; 6(4):218-25. PubMed ID: 23006993
[TBL] [Abstract][Full Text] [Related]
34. Promoting the effects of intravesical instillation of saline on bladder lesion development in rats pre-treated with BBN.
Itoh Y; Okamura T; Tozawa K; Yamada Y; Kohri K
Int J Urol; 2002 Jan; 9(1):24-8. PubMed ID: 11972646
[TBL] [Abstract][Full Text] [Related]
35. Liposome-Encapsulated Bacillus Calmette-Guérin Cell Wall Skeleton Enhances Antitumor Efficiency for Bladder Cancer In Vitro and In Vivo via Induction of AMP-Activated Protein Kinase.
Whang YM; Yoon DH; Hwang GY; Yoon H; Park SI; Choi YW; Chang IH
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33302414
[TBL] [Abstract][Full Text] [Related]
36. Anticancer benefits of early versus late use of rapamycin in a rat model of urothelial carcinoma.
Chang CH; Fu YC; Li JR; Shu KH; Ho HC; Shiu YN; Wu MJ
Transplant Proc; 2014 May; 46(4):1240-2. PubMed ID: 24815170
[TBL] [Abstract][Full Text] [Related]
37. Comparative study on antitumor effect of cell-wall skeleton of Mycobacterium bovis BCG and Nocardia rubra, with reference to T-cell dependency and independency.
Yanagawa E; Yasumoto K; Ohta M; Nomoto K; Azuma I; Yamamura Y
Gan; 1979 Apr; 70(2):141-6. PubMed ID: 381087
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of peritoneal exudate cells induced by cell-wall skeleton of Mycobacterium bovis BCG.
Namba M; Ogura T; Hirao F; Azuma I; Yamamura Y
Gan; 1978 Dec; 69(6):831-4. PubMed ID: 374173
[TBL] [Abstract][Full Text] [Related]
39. A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer.
Shibata T; Takata E; Sakamoto J; Shioya A; Yamada S; Takakura M; Sasagawa T
Medicine (Baltimore); 2022 Dec; 101(52):e32481. PubMed ID: 36595982
[TBL] [Abstract][Full Text] [Related]
40. Application of BCG-CWS as a Systemic Adjuvant by Using Nanoparticulation Technology.
Masuda H; Nakamura T; Noma Y; Harashima H
Mol Pharm; 2018 Dec; 15(12):5762-5771. PubMed ID: 30380885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
